Investor68 schreef op 23 maart 2017 13:25:
03-23-2017 06:20 AM CET - Health & Medicine
Elafibranor Could be Just the Thing to Boost the Global Non-alcoholic Steatohepatitis Therapeutics Market
There are a few key causes of a fatty liver, one of which is non-alcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance. Obesity is another factor that can significantly increase the chances of contracting NAFLD.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.comWebsite:
www.transparencymarketresearch.comThis release was published on openPR.
www.openpr.com/news/478663/Elafibrano...